# Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma

> **NCT00989352** · PHASE2 · UNKNOWN · sponsor: **University Hospital Freiburg** · enrollment: 56 (estimated)

## Conditions studied

- Primary Non Hodgkin Lymphoma of the Central Nervous System

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Lomustine
- **DRUG:** Procarbazine
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00989352
- **Lead sponsor:** University Hospital Freiburg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-09
- **Primary completion:** 2011-06
- **Final completion:** 2011-09
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2009-10-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00989352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00989352, "Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00989352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*